Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma

NCT01231906 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT01231906
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01231906 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma
Lead sponsor
Children's Oncology Group
Phase
Phase 3
Overall status
Completed
Start date
November 24, 2010
Completion date
December 31, 2025
Enrollment
642 (actual)
Sites
243

Conditions

As the registry lists them; a condition with its own page is linked.

localized extraskeletal ewing sarcoma, peripheral primitive neuroectodermal tumor of bone, peripheral primitive neuroectodermal tumor of soft tissues